I am so deeply honored to be voted into the fellowship,” he says.Īmong his other notable honors was being the first UC professor to be named a Distinguished University Research Professor in 1988 by university President Joseph Steger and the UC Board of Trustees. “This is the oldest science organization in the U.S. Schwartz counts election by AAAS as a fellow as the highest honor he has ever received among the numerous awards bestowed upon him during his lengthy career. In the time I have left I would like to assist the goals of this society.” "Most of the work my team and I accomplished I attribute to the support and encouragement I always received from UC, as well as the support by the NIH in many grants. ![]() I cannot describe how happy I am,” Schwartz says of his election as a fellow. “I am so pleased and happy to be in the same component of the AAAS as so many scientists who have gone on to win Nobels and other research awards. The digitalis drugs are the oldest pharmaceutical agents partially derived from plants. The latter was accomplished with colleagues from the College of Medicine, Gary Shull, PhD, professor emeritus, and the late Jerry Lingrel, PhD, professor, both in the Department of Molecular and Cellular Biosciences. His work on the digitalis mechanism of action led to the cloning of the high affinity receptor for the digitalis drugs, the NaK-ATPase. Schwartz also was the first to clone and characterize the human heart calcium channel and identify the receptor sites for the CCBs. ![]() ![]() He and colleagues were the first to identify and label (α1 and α2) the two major repeating chains of the L-type voltage-dependent calcium channels. These drugs have saved hundreds of thousands of lives and ameliorated the deleterious aspects of cardiovascular diseases, such as cardiac failure, hypertension and arrhythmias. Schwartz is an internationally recognized heart researcher and educator who is credited with developing multiple cardiac drug therapies, such as the calcium channel blockers (CCB) diltiazem, amlodipine and verapamil. Schwartz has been elected to the medical sciences section of AAAS and was selected for “distinguished contributions to the field of cardiovascular pharmacology, particularly for developing multiple successful drug therapies." He is one of more than 500 distinguished scientists honored as part of the 2022 AAAS fellows class. Education in Action right arrow down arrowĪrnold Schwartz, PhD, Edward Wendland Professor of Materia Medica and Therapeutics in the Department of Pharmacology and Systems Physiology at the University of Cincinnati College of Medicine, has been elected a fellow of the American Association for the Advancement of Science (AAAS).
0 Comments
Leave a Reply. |